Smarter Team

About the Author Smarter Team

Smarter Analyst was established to fill a gap in financial reporting for sell-side investors, where they can read exclusive reports in real time. Smarter Analyst provides coverage of equities research, unique analyst insights, and outstanding articles from knowledgeable contributors, in addition to the latest stock market news, all hand-picked by our editors.

Qudian Inc – ADR (QD) Continues to Lose Steam on NYSE

Qudian Inc – ADR (NYSE:QD) shares plunged again on Tuesday following concerns over the integrity and the prospects of the troubled micro-lending tycoon. …

Advanced Micro Devices, Inc. (AMD): AMD EPYC-Powered HPE DL385 Gen10 Server Is Breaking World Records

Hewlett Packard Enterprise Co (NYSE:HPE) ProLiant DL385 Gen10 server, which is powered by Advanced Micro Devices, Inc. (NASDAQ:AMD) EPYC™ processors, has set new …

Here’s Why Celsion Corporation Draws a Vote of Confidence from Oppenheimer

Celsion Corporation (NASDAQ:CLSN) investor sentiment is getting stoked today on back of new bullish attention from Oppenheimer analyst Hartaj Singh. Even though this …

Hedge Fund Guru Dmitry Balyasny Pulls the Trigger on Teva Pharmaceutical (TEVA), Synergy Pharmaceuticals (SGYP), Opko Health (OPK)

How does Hedge fund guru Dmitry Balyasny’s choice to invest new stakes in Teva Pharmaceutical (NYSE:TEVA) and Synergy Pharmaceuticals (NASDAQ:SGYP) while bumping up …

Deutsche Bank Pinpoints Uncertainties Nipping at Valeant’s Potential for Growth

Valeant Pharmaceuticals (NYSE:VRX) aced its third quarter, but while many on Wall Street were thrilled to see the biotech giant take a stride …

Maxim Bull Says xG Technology Will Make Up for 3Q Miss with 4Q Growth Recovery

xG Technology Inc (NASDAQ:XGTI) did not put its best foot forward during a third quarter that saw the company meaningfully underclass a bullish …

Mizuho Wonders if Teva Can Avoid Downgrade to High Yield After Rocky 3Q Print

Can Teva Pharmaceutical (NYSE:TEVA) recover after such a third quarter earnings fall? Mizuho analyst Irina Rivkind Koffler is left asking questions of whether …

Aurinia Has Canaccord Captivated with Voclosporin Prospects

Following a third quarter print and clinical update from Aurinia Pharmaceuticals (NASDAQ:AUPH) on its pivotal study in lupus nephritis (LN), Canaccord analyst Neil …

Calithera Sell-Off Unwarranted as Investors Ignore Positive Signal in Upcoming Breast Cancer Data

According to an abstract released on November 13th, Calithera’s (NASDAQ:CALA) Triple-Negative-Breast-Cancer appears to show a very positive signal, especially among African-American Women. However, …

Billionaire Israel “Izzy” Englander Bets on Troubled Pharma Giants Teva and Valeant, Nixes Acadia

Billionaire Israel “Izzy” Englander, who helmed his fortune from humble, Polish immigrant beginnings took a chance on two giants that have played with …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts